After seeing promising results in phase 1 of the Pediatric
Leukemia Adoptive Therapy (PLAT - 02) trial with 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50
Leukemia Adoptive Therapy (PLAT - 02) trial with 93 percent of patients with relapsed or refractory acute
lymphoblastic leukemia (ALL) achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50
leukemia (ALL)
achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50 percent.
The patient was treated on an acute
lymphoblastic leukemia (ALL) protocol for eight cycles of hyperCVAD (cyclophosphamide, vincristine, adriamycin and decadron) alternating with MTX / Ara - C (methotrexate and cytarabine) and
achieved complete remission (CR) confirmed by a bone marrow biopsy and by the resolution of most of her skin lesions.